Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Plasma Markers Predict Brain Amyloid Burden in AD

By LabMedica International staff writers
Posted on 23 Feb 2018
Aggregation and accumulation of beta-amyloid (Aβ), particularly Aβ42, is implicated in the pathogenesis of Alzheimer's disease (AD) with overproduction in autosomal-dominant AD and impaired clearance in the presence of amyloidosis contributing to the cause of AD.

Cerebrospinal fluid analysis and other measurements of amyloidosis, such as amyloid-binding positron emission tomography studies, are limited by cost and availability. More...
There is a need for a more practical beta-amyloid (Aβ) biomarker for central nervous system amyloid deposition.

An international team of scientists working with the Japanese National Center for Geriatrics and Gerontology (Obu, Japan) used immunoprecipitation followed by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry to measure levels of the three markers, APP669-711, Aβ42, and Aβ40 in two cohorts, a discovery set consisting of 121 Japanese patients and a validation set consisting of 252 Australian patients. Both sets included a mix of cognitively normal individuals, subjects with mild cognitive impairment, and subjects with clinically diagnosed Alzheimer's disease with dementia. All patients also had Aβ- positron-emission tomography (PET) imaging data, providing an assessment of their brain Aβ burdens. A subset of the Australian patients also had measurements taken of their cerebrospinal fluid Aβ levels.

The tem tested ratios of the three markers to develop a composite blood-based marker corresponding to brain Aβ levels as assessed by PET and cerebrospinal fluid (CSF) measurements. They used ratios as opposed to absolute measurements to account for individual variation in blood Aβ42 levels across individuals. A composite of the three plasma protein ratios corresponded well with both patient Aβ42 CSF levels and brain Aβ42 levels as determined by PET. Using PET measurements as the gold standard, the investigators found their plasma measurements had comparable performance to the CSF measurements, with both showing accuracy of 80.4% and areas under the curve of 83.8% and 87.4% for the blood and CSF measurements, respectively. Using the CSF measurements as the gold standard, the composite plasma markers performed with an accuracy of 80.4% and an AUC of 87.6.

The authors concluded that their results demonstrated the potential clinical utility of plasma biomarkers in predicting brain beta-amyloid burden at an individual level. These plasma biomarkers also have cost–benefit and scalability advantages over current techniques, potentially enabling broader clinical access and efficient population screening. The study was published on January 31, 2018, in the journal Nature.

Related Links:
Japanese National Center for Geriatrics and Gerontology


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Collection and Transport System
PurSafe Plus®
New
Alcohol Testing Device
Dräger Alcotest 7000
New
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Pathology

view channel
Image: Erythrocyte Sedimentation Rate Sample Stability (Photo courtesy of ALCOR Scientific)

ESR Testing Breakthrough Extends Blood Sample Stability from 4 to 28 Hours

Erythrocyte sedimentation rate (ESR) is one of the most widely ordered blood tests worldwide, helping clinicians detect and monitor infections, autoimmune conditions, cancers, and other diseases.... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.